Background
==========

An emerging concept in cardiovascular disease (CVD) prevention is a shift in focus from predicting isolated coronary events to broader prediction of any CVD event. This has led to derivation of a new Framingham CVD risk profile \[[@B1]\] beyond the traditional score for predicting 10-year coronary disease events \[[@B2]\]. To illustrate this, data from the National Health and Nutrition Examination Surveys compared the two instruments among US men and women and found that just 3% of individuals were at a high (\>20%) predicted coronary disease risk, whereas 18% were at high CVD risk when CVD death, myocardial infarction, angina, stroke, transient ischemic attack, peripheral arterial disease, and heart failure were encompassed \[[@B3]\]. This broader focus on predicting CVD risk might especially benefit ethnic minorities given higher prevalence rates of non-coronary vascular disease \[[@B4]\]. Although the prevalence of coronary disease is higher for Whites versus minorities, total CVD rates are higher among minorities, largely attributable to a higher occurrence of stroke and heart failure \[[@B4]\].

At the same time, considerable efforts have been made to improve the discriminative capacity of risk prediction tools by adding new risk factors to the models. Markers of inflammation, particularly high-sensitivity C-reactive protein (hsCRP), and measures of vascular function have received attention. The role of emerging markers has not been well explored for prediction of CVD beyond coronary disease, and data are more limited among minority populations. For instance, just 1% of subjects in both derivation and validation cohorts of a study assessing the additional predictive value of hsCRP were Latino \[[@B5]\]. Although a greater prevalence of arterial stiffness has been demonstrated in African Americans \[[@B6]\], little is known about vascular function among Latinos, the largest and fastest growing minority population in the United States \[[@B7]\]. Given this background, we evaluated inflammatory and vascular function markers in a safety-net population with chronic hypertension. We hypothesized that regardless of ethnicity, pulse wave velocity (PWV) would be associated with pre-clinical carotid atherosclerosis beyond traditional risk factors.

Methods
=======

Subject characteristics
-----------------------

The study sample consisted of 177 subjects recruited from an electronic registry of hypertension patients created as part of the Latinos Using Cardio Actions to Reduce Risk (LUCHAR) program \[[@B8]\]. Patients in the registry were regular patients at Denver Health, an integrated urban safety net health system \[[@B9]\]. Data from the registry were supplemented with chart review and patient self-report during an enrollment interview. Patients were eligible for the current study if they were ≥18 years of age, of either Latino or non-Latino White ethnicity, actively receiving antihypertensive medication, and had an established diagnosis of chronic hypertension. In addition, subjects had at least one other CVD risk factor including diabetes, dyslipidemia, obesity, chronic kidney disease, microalbuminuria, current smoking, or age \>55 for men or \>65 for women. All participants provided written informed consent in order to participate in the study. Patients were evaluated consecutively during the enrollment period and excluded if they had pre-existing CVD defined as myocardial infarction, prior percutaneous or surgical coronary revascularization, stroke, cerebrovascular revascularization, or peripheral arterial disease. Additional exclusions were valvular heart disease, end-stage renal disease, inflammatory disease, active substance abuse, or projected life expectancy \<12 months. Non-invasive vascular structure and function markers as well as inflammatory biomarkers were obtained on a single day. The Colorado Multiple Institutional Review Board approved the study protocol.

Inflammatory markers
--------------------

A venous plasma sample was obtained from all subjects. Patients were asked to fast and refrain from smoking from the night before their appointment. We chose two markers of systemic inflammation, high sensitivity C-reactive protein (hsCRP) because it has been studied extensively as a risk factor^5^and lipoprotein-associated phospholipase A2 (Lp-PLA2) given its purported specificity for inflammation localized to atherosclerotic plaque including carotid arteries \[[@B10]-[@B13]\]. Levels of Lp-PLA2 mass and activity were measured (PLAC; diaDexus Inc, South San Francisco, CA) by a dual monoclonal antibody immunoassay.^13^Samples were assayed for hsCRP with a high-sensitivity assay (hsCRP Flex^®^, Dimension Vista). This assay was validated against the Roche Hitachi Modular assay and found to have acceptable precision and reproducibility \[[@B14]\].

Vascular function measures
--------------------------

All measurements were performed in a quiet room with controlled ambient temperature. Blood pressure was measured in duplicate in the supine position using the non-dominant arm in all subjects. Brachial-ankle pulse wave velocity (PWV) was derived from the pulse transit time between and the estimated path length between proximal and distal arterial sites expressed as cm/sec. Applanation tonometry (HEM-9000AI Omron Healthcare, Bannockburn, Illinois) was performed at the radial artery to derive the augmentation index (AIx) and central aortic pressure (cAP). AIx was calculated as the difference between the first (ejection) and second (reflected) peaks of the arterial waveform, expressed as a percentage of the pulse pressure, where higher AIx values reflect greater vascular stiffness.

One ultrasonographer assessed flow-mediated dilation (FMD) of the brachial artery in the non-dominant arm, which was immobilized and scanned above the antecubital fossa using a 5-12 MHz linear array transducer (Phillips Medical Systems model iE33, Bothell, WA). Arterial images were obtained before (baseline) and after (maximal) inflation of a cuff at pressures \>40 mm Hg above systolic blood pressure for five minutes. Longitudinal images were scanned and captured (in mm) at end diastole. FMD was defined as \[maximal - baseline brachial artery diameter\] divided by baseline brachial artery diameter × 100 and expressed as percentages.

Carotid intima-media thickness
------------------------------

Measures of maximal carotid IMT were obtained in the supine position by a single ultrasonographer. Longitudinal B-mode ultrasound images were obtained among subjects with the head turned 45 degrees from the area scanned. Gain settings were optimized to acquire far wall arterial images and limit echogenicity of the lumen. A linear array probe (Phillips Sonos 5500, Netherlands) was used for all image acquisition. The sonographer obtained 3 longitudinal views of both internal carotid arteries for a total of 6 IMT images per subject as previously described \[[@B15]\]. The internal carotid artery was defined to include the bulb and the initial 10 mm of vessel distal to separation of external from internal arteries. High resolution images were stored digitally, and read off-line by trained interpreters blinded to clinical characteristics of study participants. Near and fall wall thickness were calculated as the maximum distance between the lines.

Statistical Analysis
--------------------

Mean and standard deviations for all normally distributed variables were calculated. Pulse wave velocity was normalized after transformation by the relationship P-inverse = - (1/PWV) - 0.0006)/0.00011) \[[@B16]\]. Carotid IMT was the primary outcome variable. Pearson correlation coefficients or Student\'s t-test were used to assess univariate relationships between carotid IMT and candidate independent variables. Multivariate linear regression models were used to assess the association between carotid IMT and the inflammatory, vascular stiffness, and endothelial function variables after adjusting for variables used in the Framingham general risk profile including age, gender, systolic blood pressure, anti-hypertensive medication use, total and HDL-cholesterol, diabetes, and smoking status. Because all subjects were receiving anti-hypertensive medications, this variable was not considered further. P-values \< 0.05 were considered statistically significant. Receiver operator characteristic curves to predict high carotid IMT as a dichotomous variable were also constructed for Framingham risk score, PWV, and AIx. We tested interactions with each independent variable and ethnicity in another set of models to test the hypothesis that the relationship between the outcome variables and the independent variables would be similar between Latino and non-Latino white subgroups. Following data quality assurance measures, SAS Version 8.0 (Cary, NC) was used for all statistical analyses.

Results
=======

Baseline characteristics of the sample are shown in Table [1](#T1){ref-type="table"}. The mean age was 62 years, two thirds were female and two-thirds were Latino. Nearly half had diabetes. Consistent with a sample drawn from a safety net institution, nearly half had not completed high school and over 80% were unemployed or disabled. Mean LpPLA2 was 173 ± 59 ng/ml. In contrast with hsCRP, only 21% of subjects would be classified as high-risk, using the LpPLA2 cut-point of \>200 ng/ml \[[@B17]\]. Mean hsCRP was 5.25 ± 6.65 mg/L and over 63% of the cohort would be classified as high-risk using the recently established cut-point of 2 mg/L used in the JUPITER trial \[[@B18]\]. Univariate relationships between independent variables and carotid IMT are shown in Table [2](#T2){ref-type="table"}. The inflammatory, and vascular function variables associated with cIMT at p \< 0.25 on univariate analysis were PWV, AIx, cAP and LpPLA~2~activity rank. PWV had the strongest linear relationship (r = + 0.39, p \< 0.0001) with carotid IMT (Figure [1](#F1){ref-type="fig"}). For high carotid IMT (\>0.8 mm) C-statistics assessing discrimination for PWV, AIx and Framingham risk score (adjusting for age, gender, systolic blood pressure, and ethnicity) were 0.72, 0.63, and 0.51 respectively. Results of the multiple linear regression analyses with standardised coefficients are shown in Table [3](#T3){ref-type="table"}. After adjusting for Framingham risk factors, AIx, cAP, and LpPLA2 activity were no longer significantly associated with carotid IMT (all p \> .10). Only PWV remained associated with carotid IMT independent of the Framingham general risk profile parameters (p = .016). Additional analyses indicated no statistically significant interactions between the Framingham risk factors and other independent variables and ethnicity (all p \> .05) when predicting carotid IMT. For the interaction between PWV and ethnicity when predicting carotid IMT, the p-value was 0.518.

###### 

Patient Characteristics (n = 177)

  ---------------------------------------------------------------------------- --------------------------
  Age, years                                                                   61.5 (9.7)
  Female gender                                                                66.7%
  Ethnicity                                                                    
   Hispanic                                                                    66.7%
   Non-Hispanic White                                                          33.3%
  Education                                                                    
   College graduate                                                            8.5%
   Higher education                                                            19.3%
   High school graduate                                                        19.8%
   Some high school                                                            21.5%
   No high school                                                              31.1%
  Employment Status                                                            
   Employed                                                                    19.2%
   Unemployed                                                                  46.9%
   Disabled                                                                    33.9%
  Body mass index, kg/m^2^                                                     33.0 (6.7)
  Blood pressure, mmHg                                                         142.2 ± 22.1/81.7 ± 12.3
  Total cholesterol, mg/dl                                                     181.5 (39.6)
  Triglycerides, mg/dl                                                         170.9 (105.2)
  HDL cholesterol, mg/d                                                        51.0 (12.8)
  LDL-cholesterol, mg/dl                                                       96.8 (33.3)
  Diabetes Mellitus                                                            49.2%
  Current Smoker                                                               22.0%
  Framingham risk score\*                                                      11.6 (8.0), 1-53
  LpPLA2^†^mass, ng/mL                                                         173.5 (59.0)
  LpPLA2 activity, nmol/min/mL                                                 134.8 (34.3)
  Central aortic pressure, mm Hg                                               59.5 (18.1)
  Augmentation index                                                           86.3% (12.7)
  Pulse wave velocity, cm/sec                                                  1723.3 (349)
  Flow-mediated dilation                                                       10.5% (8.1)
  Carotid intima-media thickness, mm                                           0.95 (0.22)
  Use of Hypertension Medication                                               90.4%
  Use of Hydroxy-3-methylglutaryl Co-enzyme A reductase inhibitors (statins)   59.9%
  ---------------------------------------------------------------------------- --------------------------

Values expressed as mean + standard deviation (SD) or as percentages (%). hsCRP = high sensitivity C-reactive protein. \*mean (SD) and range^†^LpPLA2 = Lipoprotein-associated phospholipase A2.

###### 

Univariate relationships with Carotid Intima Media Thickness

  N = 177                           Carotid intima-media thickness   
  --------------------------------- -------------------------------- ---------
                                    **Correlation coefficient**      **P**
                                                                     
  Age (years)                       0.369                            \<.0001
  Systolic blood pressure (mm Hg)   0.207                            0.006
  Total cholesterol (mg/dL)         0.054                            0.476
  HDL cholesterol (mg/dL)           0.096                            0.210
  Pulse wave velocity (cm/s)        0.389                            \<.0001
  Augmentation Index (%)            0.123                            0.130
  Central aortic pressure (mm Hg)   0.254                            0.005
  hsCRP (mg/L)                      -0.004                           0.959
  LPPLA2 Mass rank                  0.034                            0.653
  LPPLA2 Activity rank              0.110                            0.149
  Flow-mediated dilation (%)        -0.087                           0.270
  Gender                            -0.170                           0.007
  Current Smoker                    0.023                            0.713
  Diabetes                          -0.046                           0.461

hsCRP = high sensitivity C-reactive protein. LpPLA2 = Lipoprotein-associated phospholipase A2. HDL = high density lipoprotein

![**Relationship of pulse wave velocity to carotid intima media thickness**. The relationship between the inverse of the brachial-ankle pulse wave velocity (PWV) in cm/second and the carotid intima media thickness in mm. P-inverse is - (1/PWV) - 0.0006)/0.00011). The resulting Z (P-inverse) quantity has a mean of 0 and an SD of 1. The negative sign is used to ensure that correlations with PWV retain the same direction when compared to P-inverse.](1471-2261-11-15-1){#F1}

###### 

Multivariate relationships with carotid intima-media thickness (n = 177)

                            Framingham factors alone   Framingham factors + PWV   Framingham factors + AIx   Framingham factors + cAP   **Framingham factors + LpPLA**~**2**~                                               
  ------------------------- -------------------------- -------------------------- -------------------------- -------------------------- --------------------------------------- ------------- -------- ----------- -------- -------------
  Age                       0.074                      **\<.0001**                0.045                      **0.016**                  0.073                                   **\<.0001**   0.068    **0.004**   0.075    **\<.0001**
  Female Gender             -0.111                     **0.002**                  -0.113                     **0.001**                  -0.127                                  **0.002**     -0.144   **0.001**   -0.113   **0.002**
  Systolic BP               0.025                      0.119                      0.017                      0.323                      0.012                                   0.507         0.008    0.819       0.025    0.115
  Total Cholesterol         0.014                      0.397                      0.003                      0.862                      0.005                                   0.772         0.005    0.809       0.018    0.296
  HDL Cholesterol           0.018                      0.303                      0.022                      0.205                      0.024                                   0.201         0.024    0.245       0.017    0.322
  Current Smoker            0.011                      0.782                      -0.003                     0.937                      0.023                                   0.596         0.007    0.893       0.018    0.659
  Diabetes                  -0.008                     0.796                      -0.010                     0.745                      0.000                                   0.994         -0.025   0.562       -0.010   0.763
                                                                                                                                                                                                                            
  Pulse wave velocity                                                             0.049                      **0.016**                                                                                                      
  Augmentation Index                                                                                                                    0.021                                   0.295                                       
  Central Aortic Pressure                                                                                                                                                                     0.034    0.384                
  LpPLA~2~                                                                                                                                                                                                         -0.013   0.441

Discussion
==========

In this cross-sectional study of a mixed-ethnicity population, PWV, a measure of arterial stiffness, was associated with preclinical carotid atherosclerosis independent of Framingham risk factors. To our knowledge, this is the first study to demonstrate that PWV is associated with preclinical atherosclerosis among a Latino-predominant population. Findings were similar in both Latino and non-Latino White hypertensive subjects, suggesting that measures of arterial stiffness could play a role in CVD risk stratification within the growing US safety net population. Moreover, two other arterial stiffness measures, two inflammatory markers, and a traditional measure of endothelial function were not associated with carotid intima media thickness.

Overall, most studies to date included patients with a wide range of ages and underlying conditions but a limited range of race and ethnicity. In particular, none included substantial numbers of Latinos. Moreover, very few studies have compared the relative value of arterial stiffness, inflammatory markers, and endothelial function as correlates of CVD beyond isolated coronary disease events. An epidemiological study of 2,191 elderly (age at baseline 70-79) African American and White subjects, assessed the predictive value of PWV, ankle brachial index (ABI), and inflammatory markers (hsCRP, interleukin-6, and TNF-α) to Framingham risk factors \[[@B19]\]. The outcome variable was limited to coronary disease events. PWV, ABI, and interleukin-6 were independent predictors, and the model with the best discriminative capacity added both ABI and interleukin-6 to Framingham factors. These results differ from our finding that PWV was associated with preclinical cardiovascular disease whereas inflammatory markers were not. By contrast, a study of 558 patients with hypertension and without baseline CVD, added PWV and FMD in Cox multi-variable models that had occurrence of CVD events including stroke as the outcome variable \[[@B20]\]. PWV was related to the occurrence of CVD events while FMD was not, consistent with the results of the current study in a similar hypertensive cohort. Our findings are also consistent with the current consensus opinion that PWV is the gold standard method for assessing arterial stiffness \[[@B21]\].

Our results extend to a multi-ethnic population findings of an association between arterial stiffness and cardiovascular outcomes. In a recent meta-analysis, Vlachopoulos et al \[[@B22]\] combined results of 17 longitudinal studies and found a relative risk of 1.47 for cardiovascular events associated with each standard deviation increase in PWV. These 17 studies varied in the degree to which they accounted for Framingham risk factors and in the degree to which they considered a full range of non-coronary CVD outcomes. The most comprehensive study was performed by Mitchell et al \[[@B16]\], and was consistent with our study in that PWV, but not AIx or cAP, was a significant predictor of CVD events independent of the Framingham general risk profile parameters.

A number of factors should be considered in interpreting the results of the current investigation. This was a cross-sectional study and was not powered to predict CVD events. With a larger sample size, additional vascular function variables could have reached statistical significance. Relative to PWV, however, cAP and AIx are less direct measures of arterial stiffness, more sensitive to differences in heart rate and body size, and may be more technically challenging to measure thereby limiting their utility in risk stratification. The suggestion that LpPLA~2~may have greater predictive value than hsCRP in high-risk populations deserves further exploration since hsCRP values were uniformly elevated in this safety net population. The absence of even a univariate association between hsCRP and carotid IMT in the current study is informative given the widespread use of this marker in clinical practice. A recent guideline affirms that measurement of hsCRP is not recommended for risk stratification in asymptomatic higher-risk adults, nor among older low-risk adults \[[@B23]\]. Confirmatory longitudinal studies comparing vascular function and inflammatory markers as predictors of CVD in samples with mixed race and ethnicity are needed to better assess the strength and clinical implications of this association. In addition, the prognostic significance of brachial-ankle PWV is less established compared with carotid-femoral PWV. However, brachial-ankle PWV, is more easily obtained and has been shown to be highly correlated (r = 0.76, p \< 0.0001) with carotid-femoral PWV values among hypertensive patients \[[@B24]\]. Because of its strong relationship with aortic pulse wave velocity, brachial-ankle PWV measurements offers both practical and theoretic advantages over the more frequently used carotid-femoral method \[[@B25]\], though confirmatory studies with carotid-femoral PWV are warranted. One strength of the current analysis is its focus on a traditionally under-studied safety net population. Evaluating sociodemographically vulnerable subjects serves to broaden the applicability of research findings to those individuals typically excluded from research trials; in our study, the majority of participants were women and Latinos in marked contrast to typical cardiovascular trials \[[@B26]\].

Conclusions
===========

Despite its strong association with cardiovascular mortality among hypertensive patients \[[@B27]\] and endorsement as a gold standard for vascular stiffness, the value of PWV as a therapeutic target remains uncertain. Nonetheless, our study demonstrates that PWV, in contrast to inflammatory biomarkers, has predictive value for preclinical atherosclerosis beyond the Framingham risk profile among subjects of mixed ethnicity. Given ongoing concerns about the inaccuracy of the Framingham risk score in racial/ethnic minorities \[[@B28]\] and the importance of considering overall CVD risk in such individuals, PWV warrants further evaluation in both epidemiologic and interventional studies.
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